Obesity and diabetes drugs
These companies develop and sell drugs for obesity and type 2 diabetes, such as GLP-1 and amylin treatments.
+41.2%
over 1 year · S&P 500 +11.6%
Key indicators
Health
47 / 100
Fragile
Solid
Price
P/E 34
Cheap
Expensive
Up over 1 year
8 of 17
Wallets over 90 days
2 / 5 buys / sells
Buys
Sells
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 19 companies
LLY
+42.7%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
L
Eli Lilly
LLY
82.6%
+42.7%
A
Amgen
AMGN
15.4%
+42.3%
R
Rhythm Pharmaceuticals
RYTM
0.5%
+17.5%
H
Hims & Hers
HIMS
0.3%
−49.4%
A
Amylyx Pharmaceuticals
AMLX
0.3%
+145.7%
V
Viking Therapeutics
VKTX
0.2%
−28.3%
M
MBX Biosciences
MBX
0.2%
+127.4%
S
Septerna
SEPN
0.1%
+121.5%
K
Kailera Therapeutics
KLRA
0.1%
G
Structure Therapeutics
GPCR
<0.1%
−44.3%
M
MannKind
MNKD
<0.1%
−21.3%
L
Lexicon Pharmaceuticals
LXRX
<0.1%
+16.2%
W
Wave Life Sciences
WVE
<0.1%
−55.0%
A
Altimmune
ALT
<0.1%
−61.1%
B
BioAge Labs
BIOA
<0.1%
−30.7%
C
Corbus Pharmaceuticals
CRBP
<0.1%
−69.7%
A
Amanat Acquisition Corp Class A Ordinary Shares
AMAN
N
Novo Nordisk
NVO
−14.4%
R
Dr. Reddy's Laboratories
RDY
+7.0%